The discovery and development of gefapixant.

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Autonomic Neuroscience: Basic & Clinical

• Publication date

  2021-07-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.autneu.2021.102859PMID 34403981
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

  2020cited by this paper
• Update of P2X receptor properties and their pharmacology: IUPHAR Review 30

  2020cited by this paper
• Looking ahead to novel therapies for chronic cough. Part 1 – peripheral sensory nerve targeted treatments

  2020cited by this paper
• Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.

  2020cited by this paper
• Gefapixant in two randomised dose-escalation studies in chronic cough

  2020cited by this paper
• Targeting C-fibers for peripheral acting anti-tussive drugs.

  2019cited by this paper
• Action of MK‐7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation

  2019cited by this paper
• BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.

  2019cited by this paper
• Identification of second-generation P2X3 antagonists for treatment of pain.

  2018cited by this paper
• Druggable negative allosteric site of P2X3 receptors

  2018cited by this paper
• Vagal Afferent Innervation of the Airways in Health and Disease.

  2016cited by this paper
• X-ray structures define human P2X3 receptor gating cycle and antagonist action

  2016cited by this paper
• Purinergic Mechanisms and Pain.

  2016cited by this paper
• Postsynaptic P2X3‐containing receptors in gustatory nerve fibres mediate responses to all taste qualities in mice

  2015cited by this paper
• P2X3 receptors and sensitization of autonomic reflexes.

  2015cited by this paper
• P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

  2015cited by this paper
• Anatomy and Neurophysiology of Cough

  2014cited by this paper
• Antitussive Drugs—Past, Present, and Future

  2014cited by this paper
• The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders

  2013cited by this paper
• P2X3 antagonists: novel therapeutics for afferent sensitization and chronic pain.

  2012cited by this paper
• Purinergic Signaling in the Airways

  2012cited by this paper
• Targeting peripheral afferent nerve terminals for cough and dyspnea.

  2011cited by this paper
• ATP and P2X purinoceptors in urinary tract disorders.

  2011cited by this paper
• In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization

  2011cited by this paper
• Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.

  2011cited by this paper
• The therapeutic potential of purinergic signalling.

  2010cited by this paper
• Extracellular adenosine triphosphate and chronic obstructive pulmonary disease.

  2010cited by this paper
• AF‐353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist

  2010cited by this paper
• Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

  2009cited by this paper
• Extracellular ATP in the Immune System: More Than Just a “Danger Signal”

  2009cited by this paper
• P2X2 receptors differentiate placodal vs. neural crest C-fiber phenotypes innervating guinea pig lungs and esophagus.

  2008cited by this paper
• Pharmacology of P2X channels

  2006cited by this paper
• Involvement of ionotropic purinergic receptors in the histamine-induced enhancement of the cough reflex sensitivity in guinea pigs.

  2006cited by this paper
• Purinoceptors as therapeutic targets for lower urinary tract dysfunction

  2006cited by this paper
• Involvement of P2X receptor subtypes in ATP-induced enhancement of the cough reflex sensitivity.

  2005cited by this paper
• P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP

  2005cited by this paper
• ATP Signaling Is Crucial for Communication from Taste Buds to Gustatory Nerves

  2005cited by this paper
• Effects of aerosolized adenosine 5'-triphosphate vs adenosine 5'-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma.

  2005cited by this paper
• Subtypes of vagal afferent C‐fibres in guinea‐pig lungs

  2004cited by this paper
• 2′, 3′‐O‐(2,4,6,Trinitrophenyl)‐ATP and A‐317491 are competitive antagonists at a slowly desensitizing chimeric human P2X3 receptor

  2003cited by this paper
• P2X2 subunits contribute to fast synaptic excitation in myenteric neurons of the mouse small intestine

  2003cited by this paper
• Peristalsis is impaired in the small intestine of mice lacking the P2X3 subunit

  2003cited by this paper
• A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat

  2002cited by this paper
• Purine and pyrimidine (P2) receptors as drug targets.

  2002cited by this paper
• P2X receptors in peripheral neurons.

  2001cited by this paper
• Changes in P2X receptor responses of sensory neurons from P2X3‐deficient mice

  2001cited by this paper
• Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X 3-deficient mice

  2000cited by this paper
• Regulated expression of the rat recombinant P2X(3) receptor in stably transfected CHO-K1 tTA cells.

  2000cited by this paper
• Pharmacological characterization of recombinant human and rat P2X receptor subtypes.

  1999cited by this paper
• The expression of P2X3 purinoreceptors in sensory neurons: effects of axotomy and glial-derived neurotrophic factor.

  1998cited by this paper
• P2X3 is expressed by DRG neurons that terminate in inner lamina II

  1998cited by this paper
• Immunohistochemical study of the P2X2 and P2X3 receptor subunits in rat and monkey sensory neurons and their central terminals.

  1997cited by this paper
• The Cytolytic P2Z Receptor for Extracellular ATP Identified as a P2X Receptor (P2X7)

  1996cited by this paper
• Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons

  1995cited by this paper
• Characterization and chromosomal localization of a human P2X receptor from the urinary bladder.

  1995cited by this paper
• A P2X purinoceptor cDNA conferring a novel pharmacological profile

  1995cited by this paper
• A P2X purinoceptor expressed by a subset of sensory neurons

  1995cited by this paper
• Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy.

  1994cited by this paper
• A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP

  1994cited by this paper
• New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor

  1994cited by this paper
• Is there a basis for distinguishing two types of P2-purinoceptor?

  1985cited by this paper
• Atropine resistant excitation of the urinary bladder: the possibility of transmission via nerves releasing a purine nucleotide

  1972cited by this paper
• The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart 1

  1929cited by this paper

• Gefapixant Citrate, a Selective P2X3 Receptor Antagonist, May Improve Cancer-Related Hypergeusia: A Case Report.

  2025cites this paper
• The discovery and development of gefapixant as a novel antitussive therapy

  2024influential citation
• Gefapixant, a Novel P2X3 Antagonist, Protects against Post Myocardial Infarction Cardiac Dysfunction and Remodeling Via Suppressing NLRP3 Inflammasome

  2023cites this paper
• Chronic cough relief by allosteric modulation of P2X3 without taste disturbance

  2023cites this paper
• ATP, an attractive target for the treatment of refractory chronic cough

  2022cites this paper
• AI-based prediction of new binding site and virtual screening for the discovery of novel P2X3 receptor antagonists.

  2022cites this paper
• Inspired by Geoff Burnstock - A special issue of autonomic neuroscience.

  2022cites this paper
• Emerging drugs for the treatment of bladder storage dysfunction

  2022cites this paper
• Neural control of the lower airways: Role in cough and airway inflammatory disease.

  2022cites this paper
• Dihydropyridines Potentiate ATP-Induced Currents Mediated by the Full-Length Human P2X5 Receptor

  2022cites this paper
• Gefapixant: First Approval

  2022cites this paper
• Molecular Pharmacology of P2X Receptors: Exploring Druggable Domains Revealed by Structural Biology

  2022cites this paper